View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMednow 배당 및 자사주 매입배당 기준 점검 0/6Mednow 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0.02%자사주 매입 수익률총 주주 수익률0.02%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Nov 03Mednow Announces Notice Received from Secured CreditorMednow Inc. announced that it has received a notice of default, demand and intention to enforce security from its related secured creditor Alirey Corp. amounting to $3.23 million. Mednow intends to cooperate with secured creditor to facilitate a transitional plan.공시 • Oct 31+ 1 more updateMednow Announces Executive ChangesMednow Inc. announces that Ali Reyhany has stepped down as CEO, President and Director. Felipe Campusano has also resigned as a Director, Treasurer and Secretary.공시 • Oct 24Mednow Inc. announced that it has received CAD 0.85 million in fundingOn October 23, 2023 Mednow Inc. closed the transaction. The company has amended the terms of the transaction and received gross proceeds of CAD 850,000. Ali Reyhany, CEO and Co-Founder, invested CAD 850,000 pursuant to the Offering.공시 • Sep 20Mednow Inc. Announces the Execution of Cost Reductions Through the Wind-Down of A SubsidiaryMednow Inc. announced that Infusicare Inc. has permanently ceased ordinary course business operations. Infusicare’s shutdown is part of Mednow’s ongoing efforts to improve its business by, among other things, eliminating underperforming business lines, in accordance with its previous announcements. Mednow has also received a demand letter from a supplier for $1.5 million. Mednow is in continued discussions with the supplier.공시 • Sep 05Mednow Announces Board Member ResignationsMednow Inc. announced that Kia Besharat and Mahdi Shams have stepped down as directors of the company to pursue other opportunities.공시 • Aug 03Mednow Inc. announced that it has received CAD 0.4 million in fundingOn August 1, 2023, Mednow Inc. closed the transaction.공시 • Jul 29Mednow Inc. announced that it expects to receive CAD 0.4 million in fundingMednow Inc. announced private placement of a secured convertible debenture for gross proceeds of CAD 400,000 on July 28, 2023. The transaction will include participation from Ali Reyhany, the Chief Executive Officer of the company. The debenture will bear interest at a rate of 12.0% per annum and mature 18 months following the date of issuance. The principal amount of the convertible debenture will be convertible into 5,263 units based on a conversion price of CAD 0.30 per unit. Each unit will be comprised of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.38 per common share for a period of 48 months from the date of issuance thereof, subject to applicable policies of the TSX Venture Exchange. The convertible debenture will be convertible at the option of the holder at any time during the period beginning on the later of the four month anniversary of the date of issuance of the convertible debenture; and the date on which the company completes an equity financing with aggregate proceeds to the company of at least CAD 4,000,000, and ending on the maturity date. The debenture will rank senior, secured by all of the assets and property of the company. The debenture to be issued pursuant to the transaction are subject to a statutory hold period of four months from the date of issuance. The transaction remains subject to receipt of TSX Venture Exchange approval and all other necessary regulatory approvals.Reported Earnings • Jul 01Third quarter 2023 earnings released: CA$0.19 loss per share (vs CA$0.26 loss in 3Q 2022)Third quarter 2023 results: CA$0.19 loss per share (improved from CA$0.26 loss in 3Q 2022). Revenue: CA$12.8m (up 108% from 3Q 2022). Net loss: CA$4.01m (loss narrowed 29% from 3Q 2022).공시 • May 17Mednow Inc. announced that it expects to receive CAD 0.585 million in fundingMednow Inc. announced a non-brokered private placement of up to 2,166,667 units at a price of CAD 0.27 per unit for the gross proceeds of CAD 585,000 on May 15, 2023. The transaction included participation from individual investor, Ali Reyhany for CAD 300,000. The Company paid finder’s fees of $23,400, issued 86,666 finder’s warrants and paid a fiscal advisory fee through the issuance of 86,666 units. Each Finder’s warrant is exercisable to acquire one unit at the unit price for a period of 5 years from the Closing Date. All securities issued pursuant to the Private Placement will be subject to a four-month hold period from the date of issuance.공시 • May 16Mednow Inc. has completed a Composite Units Offering in the amount of CAD 0.525262 million.Mednow Inc. has completed a Composite Units Offering in the amount of CAD 0.525262 million. Security Name: Units Security Type: Equity/Derivative Unit Price\Range: CAD 0.27 Discount Per Security: CAD 0.0216 Security Name: Units Security Type: Equity/Derivative Unit Price\Range: CAD 0.27 Discount Per Security: CAD 0.0108Reported Earnings • Apr 26Second quarter 2023 earnings released: CA$0.20 loss per share (vs CA$0.26 loss in 2Q 2022)Second quarter 2023 results: CA$0.20 loss per share (improved from CA$0.26 loss in 2Q 2022). Revenue: CA$11.3m (up 466% from 2Q 2022). Net loss: CA$4.20m (loss narrowed 26% from 2Q 2022).공시 • Jan 24Mednow Inc. Supports Expanded Scope of Practice for Ontario PharmacistsMednow Inc. is supportive of the new expanded scope of practice for Ontario pharmacists. As of January 1st, pharmacists in Ontario are now able to better support patients by assessing and prescribing treatment for 13 minor conditions. These conditions include: hives, cold sores, urinary tract infections and pink eye, among others. These services are available for patients with a valid Ontario health card. There is no out-of-pocket charge for patients as this initiative is publicly funded. The expanded scope of practice for Ontario pharmacists will allow Mednow to expand its virtual care program to include pharmacist-led prescribing. The existing Nurse Practitioner led Mednow Virtual Care service has been issuing prescriptions where appropriate, ordering lab work and making referrals at no cost to Mednow patients. The interdisciplinary and digital first model of patient care has been successful in providing convenient and accessible care to the patients. Pharmacists prescribing for these minor ailments will provide not only improved team based care for the clients, but realizes cost savings in wages and open a new revenue stream into the existing built infrastructure for Mednow, who will be reimbursed under the Ontario Drug Benefits Program for these prescribing services. This new service available at Mednow complements the recently announced pharmacist in-home medication cabinet clean up and medication review program. Mednow believes patients can receive amazing care in limited circumstances and as governments lean more and more on allied healthcare to help the stressed system, Mednow will be at the forefront of this evolution. Minor ailments can often be managed with self-care strategies and minimal treatment or follow-up required. Pharmacists can offer timely services to patients, helping Ontarians avoid wait times.Reported Earnings • Jan 19First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: CA$9.72m (up CA$9.15m from 1Q 2022). Net loss: CA$4.52m (loss widened 1.9% from 1Q 2022).공시 • Jan 18Mednow Inc. Expands Suite of ServicesMednow Inc. has expanded its suite of services to its at-home Medvisit and other patients. Medvisit's expanded suite of services includes an at-home medication review program for patients who are not physically able to attend a community pharmacy. The addition of the at-home medication review program, conducted by team of licensed traveling pharmacists, allows the physician who will see the patient afterwards to focus on treating the patient and not on performing a medication history. Pharmacists are experts in drug therapy and can help as part of the medical team to make processes more efficient. The service is covered for eligible and consenting patients by the Ontario Drug Benefits Program. It is an example of non-dispensing related revenue available to pharmacies in Canada's largest province. Medvisit is Canada's largest and longest standing doctor house call service, having been in operation for over 30 years. Medvisit conducts approximately 30,000 patient home visits per year and has served over 400,000 patients since inception. Patients that are unable to leave their home rely on over 100 doctors in the Medvisit network for the treatment of acute and episodic illness and injury. The combination of pharmacy and doctor home visits through the Mednow platform has created synergies that greatly benefit patients. By offering a comprehensive review of their medications and treatment plan prior to in-home medication visits, Mednow and Medvisit are able to provide the highest level of care at the forefront of chronic disease management. Through the Medvisit patient network, Mednow is well positioned to offer a full platform of services to a large subset of patients that can benefit greatly from a full suite of digital healthcare and delivery services. Mednow is focused on improving delivery of pharmacy services in Canada through digitization to provide better patient access to pharmacists, doctors and other healthcare professionals. Mednow offers instant access to pharmacists in the Mednow app (Apple | Android | web browser) or on the phone (1-855-MEDNOW-1) and offers fast, free delivery of prescription medication to patients across Canada.Reported Earnings • Dec 01Full year 2022 earnings released: CA$1.37 loss per share (vs CA$0.49 loss in FY 2021)Full year 2022 results: CA$1.37 loss per share (further deteriorated from CA$0.49 loss in FY 2021). Revenue: CA$16.6m (up CA$16.2m from FY 2021). Net loss: CA$29.6m (loss widened 230% from FY 2021).공시 • Jun 16+ 1 more updateMednow Inc. Announces CEO ChangesMednow Inc. announced that Ali Reyhany, the company’s current director, President and Chairman of the board, has been selected to replace Karim Nassar, as Chief Executive Officer effective June 15. As the company’s founder and architect of its culture, the Company’s board of directors believes Mr. Reyhany is singularly qualified to serve as Chief Executive Officer.Reported Earnings • Jun 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: CA$6.14m (up CA$6.01m from 3Q 2021). Net loss: CA$5.66m (loss widened 159% from 3Q 2021).공시 • Apr 27Mednow Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year Ending April 30, 2022Mednow Inc. provided earnings guidance for the third quarter of fiscal year ending April 30, 2022. For the quarter, Company expects revenue of $5 million to $5.5 million.공시 • Apr 16Mednow Inc., Annual General Meeting, Jun 07, 2022Mednow Inc., Annual General Meeting, Jun 07, 2022. Location: 10th Floor, 595 Howe Street, BC V6C Vancouver Canada공시 • Apr 03Mednow Inc. (TSXV:MNOW) completed the acquisition of Mednow East Inc. from Amir Ali Reyhany-Bozorg, Felipe Campusano and Karim Nassar and others.Mednow Inc. (TSXV:MNOW) entered into a share purchase agreement to acquire Mednow East Inc. for CAD 1.4 million from Amir Ali Reyhany-Bozorg, Felipe Campusano and Karim Nassar and others on March 4, 2022. Mednow Inc. shall acquire all of the issued and outstanding shares of Mednow East, in consideration for an aggregate cash payment of approximately CAD 65,578 and the Company’s agreement to convert approximately CAD 1,374,422 owed by Mednow East to the Mednow Inc. into a non-interest bearing on-demand convertible promissory note and the Note can be satisfied by the payment of cash or the issuance of 2,095 Class A Special Shares of Mednow East at a deemed price of $655.78 per share. Upon closing of the Share Purchase Agreement, Mednow East’s revenue and expenses will be consolidated with those of Mednow and the Pharmacy Agreement between the two parties will be terminated. The debt of approximately CAD 1,374,422 extended to Mednow East by the Company was used to fund Mednow East’s working capital and provide support for its operations. The Transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval. Mednow Inc. (TSXV:MNOW) completed the acquisition of Mednow East Inc. from Amir Ali Reyhany-Bozorg, Felipe Campusano and Karim Nassar and others on April 1, 2022.공시 • Feb 25Mednow Inc. Provides Earnings Guidance for the Years of 2022 and 2023Mednow Inc. provided earnings guidance for the years of 2022 and 2023. For the calendar year 2022, revenue is forecasted to range between CAD 42.5 million to CAD 47.5 million. Revenue for 2023 is forecasted to range between CAD 105 million to CAD 110 million.공시 • Feb 24Mednow Inc. (TSXV:MNOW) completed the acquisition of Liver Care Canada Inc.Mednow Inc. (TSXV:MNOW) entered into an agreement to acquire Liver Care Canada Inc. for CAD 0.07 million on December 20, 2021. In a related transaction, Mednow entered into an agreement to acquire London Pharmacare. Under the agreement, Mednow will acquire Liver Care for an initial cash payment of CAD 0.07 million and two subsequent earnout payments in the amount of 0.1x of the revenue generated by Liver Care in each of its 2022 and 2023 financial years. The Transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval. Mednow Inc. (TSXV:MNOW) completed the acquisition of Liver Care Canada Inc. on February 23, 2022.공시 • Dec 23Mednow Inc. (TSXV:MNOW) entered into a share purchase agreement to acquire London Pharmacare Inc. from Felipe Campusano and others for CAD 0.59 million.Mednow Inc. (TSXV:MNOW) entered into a share purchase agreement to acquire London Pharmacare Inc. from Felipe Campusano and others for CAD 0.59 million on December 20, 2021. The consideration includes an initial cash payment of CAD 0.59 million and two subsequent earn-out payments in the amount of 0.1x of the revenue generated by London Pharmacare in each of its 2022 and 2023 financial years. In a related transaction, Mednow entered into an agreement to acquire Liver Care Canada Inc. for CAD 0.07 million. In the last fiscal year, London Pharmacare and Liver Care Canada generated approximately an aggregate of CAD 21.3 million in revenue and CAD 2.1 million in gross profits from selling prescription medications and diagnostic services to its patients. The transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval.공시 • Dec 22Mednow Inc. (TSXV:MNOW) entered into an agreement to acquire Liver Care Canada Inc. for CAD 0.07 million.Mednow Inc. (TSXV:MNOW) entered into an agreement to acquire Liver Care Canada Inc. for CAD 0.07 million on December 20, 2021. In a related transaction, Mednow entered into an agreement to acquire London Pharmacare. Under the agreement, Mednow will acquire Liver Care for an initial cash payment of CAD 0.07 million and two subsequent earnout payments in the amount of 0.1x of the revenue generated by Liver Care in each of its 2022 and 2023 financial years. The Transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval.공시 • Dec 14Mednow Inc. (TSXV:MNOW) completed the acquisition of Infusicare Canada Inc. from Amir Ali Reyany-Bozorg, Felipe Campusano and others for CAD 1.9 million.Mednow Inc. (TSXV:MNOW) entered into an agreement to acquire Infusicare Canada Inc. from Amir Ali Reyany-Bozorg, Felipe Campusano and others for CAD 1.9 million on November 18, 2021. The consideration will be paid in cash. Infusicare Canada generated revenues of CAD 9.3 million in fiscal year 2020. The transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval. Mednow Inc. (TSXV:MNOW) completed the acquisition of Infusicare Canada Inc. from Amir Ali Reyany-Bozorg, Felipe Campusano and others on December 13, 2021.공시 • Sep 24Mednow Inc. (TSXV:MNOW) entered into a share purchase agreement to acquire Mednow Pharmacy Inc. from Amir Ali Reyhany-Bozorg, Karim Nassar and Felipe Campusano for CAD 0.074 million.Mednow Inc. (TSXV:MNOW) entered into a share purchase agreement to acquire Mednow Pharmacy Inc. from Amir Ali Reyhany-Bozorg, Karim Nassar and Felipe Campusano for CAD 0.074 million on September 22, 2021. As part of consideration, Mednow Inc. will pay CAD 0.074 million in cash. Post-acquisition, Mednow will own 100% of Mednow Pharmacy Inc. The transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval.공시 • Aug 08Mednow Inc. (TSXV:MNOW) acquired 2716725 Ontario Inc. for CAD 2 million.Mednow Inc. (TSXV:MNOW) acquired 2716725 Ontario Inc. for CAD 2 million on August 6, 2021. Under the terms of transaction, Mednow will pay CAD 1.32 million in cash upon closing and a conditional earn-out of up to CAD 0.68 million subject to profitability milestones. In latest fiscal year, Medvisit earned revenue of approximately CAD 3 million and a gross profit of approximately CAD 0.79 million. Mednow Inc. (TSXV:MNOW) completed the acquisition of 2716725 Ontario Inc. on August 6, 2021.분석 기사 • Jun 24Is Mednow (CVE:MNOW) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Executive Departure • Jun 10Chief Financial Officer Joshua Lebovic has left the companyDuring their tenure, earnings grew by 609% annually compared to the industry average of 117%. We don't have any record of a personal shareholding under Joshua's name. Joshua is the only executive to leave the company over the last 12 months.공시 • Mar 21Mednow Inc. Appoints Carey Lai as Director of Pharmacy OperationsMednow Inc. announced a significant operational milestone in advancing its national expansion strategy. Mednow has filed an application for a pharmacy license with the Manitoba College of Pharmacists through a wholly-owned subsidiary, Mednow Pharmacy MB Ltd. Upon successful application, this wholly-owned entity will be a licensed pharmacy that will be regulated by Manitoba College of Pharmacists as well as provincial and federal regulatory bodies with oversight of pharmacy practices. In conjunction with this application, the Company has appointed Carey Lai as Director of Pharmacy Operations for Manitoba and Saskatchewan. Mr. Lai has over 15 years’ experience in pharmacy operations.분석 기사 • Mar 11We're Hopeful That Mednow (CVE:MNOW) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 MNOW 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: MNOW 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Mednow 배당 수익률 vs 시장MNOW의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (MNOW)n/a시장 하위 25% (CA)1.7%시장 상위 25% (CA)5.5%업계 평균 (Consumer Retailing)1.1%분석가 예측 (MNOW) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 MNOW 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 MNOW 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 MNOW 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: MNOW 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCA 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/01/30 06:56종가2023/11/02 00:00수익2023/04/30연간 수익2022/07/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Mednow Inc.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Nov 03Mednow Announces Notice Received from Secured CreditorMednow Inc. announced that it has received a notice of default, demand and intention to enforce security from its related secured creditor Alirey Corp. amounting to $3.23 million. Mednow intends to cooperate with secured creditor to facilitate a transitional plan.
공시 • Oct 31+ 1 more updateMednow Announces Executive ChangesMednow Inc. announces that Ali Reyhany has stepped down as CEO, President and Director. Felipe Campusano has also resigned as a Director, Treasurer and Secretary.
공시 • Oct 24Mednow Inc. announced that it has received CAD 0.85 million in fundingOn October 23, 2023 Mednow Inc. closed the transaction. The company has amended the terms of the transaction and received gross proceeds of CAD 850,000. Ali Reyhany, CEO and Co-Founder, invested CAD 850,000 pursuant to the Offering.
공시 • Sep 20Mednow Inc. Announces the Execution of Cost Reductions Through the Wind-Down of A SubsidiaryMednow Inc. announced that Infusicare Inc. has permanently ceased ordinary course business operations. Infusicare’s shutdown is part of Mednow’s ongoing efforts to improve its business by, among other things, eliminating underperforming business lines, in accordance with its previous announcements. Mednow has also received a demand letter from a supplier for $1.5 million. Mednow is in continued discussions with the supplier.
공시 • Sep 05Mednow Announces Board Member ResignationsMednow Inc. announced that Kia Besharat and Mahdi Shams have stepped down as directors of the company to pursue other opportunities.
공시 • Aug 03Mednow Inc. announced that it has received CAD 0.4 million in fundingOn August 1, 2023, Mednow Inc. closed the transaction.
공시 • Jul 29Mednow Inc. announced that it expects to receive CAD 0.4 million in fundingMednow Inc. announced private placement of a secured convertible debenture for gross proceeds of CAD 400,000 on July 28, 2023. The transaction will include participation from Ali Reyhany, the Chief Executive Officer of the company. The debenture will bear interest at a rate of 12.0% per annum and mature 18 months following the date of issuance. The principal amount of the convertible debenture will be convertible into 5,263 units based on a conversion price of CAD 0.30 per unit. Each unit will be comprised of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.38 per common share for a period of 48 months from the date of issuance thereof, subject to applicable policies of the TSX Venture Exchange. The convertible debenture will be convertible at the option of the holder at any time during the period beginning on the later of the four month anniversary of the date of issuance of the convertible debenture; and the date on which the company completes an equity financing with aggregate proceeds to the company of at least CAD 4,000,000, and ending on the maturity date. The debenture will rank senior, secured by all of the assets and property of the company. The debenture to be issued pursuant to the transaction are subject to a statutory hold period of four months from the date of issuance. The transaction remains subject to receipt of TSX Venture Exchange approval and all other necessary regulatory approvals.
Reported Earnings • Jul 01Third quarter 2023 earnings released: CA$0.19 loss per share (vs CA$0.26 loss in 3Q 2022)Third quarter 2023 results: CA$0.19 loss per share (improved from CA$0.26 loss in 3Q 2022). Revenue: CA$12.8m (up 108% from 3Q 2022). Net loss: CA$4.01m (loss narrowed 29% from 3Q 2022).
공시 • May 17Mednow Inc. announced that it expects to receive CAD 0.585 million in fundingMednow Inc. announced a non-brokered private placement of up to 2,166,667 units at a price of CAD 0.27 per unit for the gross proceeds of CAD 585,000 on May 15, 2023. The transaction included participation from individual investor, Ali Reyhany for CAD 300,000. The Company paid finder’s fees of $23,400, issued 86,666 finder’s warrants and paid a fiscal advisory fee through the issuance of 86,666 units. Each Finder’s warrant is exercisable to acquire one unit at the unit price for a period of 5 years from the Closing Date. All securities issued pursuant to the Private Placement will be subject to a four-month hold period from the date of issuance.
공시 • May 16Mednow Inc. has completed a Composite Units Offering in the amount of CAD 0.525262 million.Mednow Inc. has completed a Composite Units Offering in the amount of CAD 0.525262 million. Security Name: Units Security Type: Equity/Derivative Unit Price\Range: CAD 0.27 Discount Per Security: CAD 0.0216 Security Name: Units Security Type: Equity/Derivative Unit Price\Range: CAD 0.27 Discount Per Security: CAD 0.0108
Reported Earnings • Apr 26Second quarter 2023 earnings released: CA$0.20 loss per share (vs CA$0.26 loss in 2Q 2022)Second quarter 2023 results: CA$0.20 loss per share (improved from CA$0.26 loss in 2Q 2022). Revenue: CA$11.3m (up 466% from 2Q 2022). Net loss: CA$4.20m (loss narrowed 26% from 2Q 2022).
공시 • Jan 24Mednow Inc. Supports Expanded Scope of Practice for Ontario PharmacistsMednow Inc. is supportive of the new expanded scope of practice for Ontario pharmacists. As of January 1st, pharmacists in Ontario are now able to better support patients by assessing and prescribing treatment for 13 minor conditions. These conditions include: hives, cold sores, urinary tract infections and pink eye, among others. These services are available for patients with a valid Ontario health card. There is no out-of-pocket charge for patients as this initiative is publicly funded. The expanded scope of practice for Ontario pharmacists will allow Mednow to expand its virtual care program to include pharmacist-led prescribing. The existing Nurse Practitioner led Mednow Virtual Care service has been issuing prescriptions where appropriate, ordering lab work and making referrals at no cost to Mednow patients. The interdisciplinary and digital first model of patient care has been successful in providing convenient and accessible care to the patients. Pharmacists prescribing for these minor ailments will provide not only improved team based care for the clients, but realizes cost savings in wages and open a new revenue stream into the existing built infrastructure for Mednow, who will be reimbursed under the Ontario Drug Benefits Program for these prescribing services. This new service available at Mednow complements the recently announced pharmacist in-home medication cabinet clean up and medication review program. Mednow believes patients can receive amazing care in limited circumstances and as governments lean more and more on allied healthcare to help the stressed system, Mednow will be at the forefront of this evolution. Minor ailments can often be managed with self-care strategies and minimal treatment or follow-up required. Pharmacists can offer timely services to patients, helping Ontarians avoid wait times.
Reported Earnings • Jan 19First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: CA$9.72m (up CA$9.15m from 1Q 2022). Net loss: CA$4.52m (loss widened 1.9% from 1Q 2022).
공시 • Jan 18Mednow Inc. Expands Suite of ServicesMednow Inc. has expanded its suite of services to its at-home Medvisit and other patients. Medvisit's expanded suite of services includes an at-home medication review program for patients who are not physically able to attend a community pharmacy. The addition of the at-home medication review program, conducted by team of licensed traveling pharmacists, allows the physician who will see the patient afterwards to focus on treating the patient and not on performing a medication history. Pharmacists are experts in drug therapy and can help as part of the medical team to make processes more efficient. The service is covered for eligible and consenting patients by the Ontario Drug Benefits Program. It is an example of non-dispensing related revenue available to pharmacies in Canada's largest province. Medvisit is Canada's largest and longest standing doctor house call service, having been in operation for over 30 years. Medvisit conducts approximately 30,000 patient home visits per year and has served over 400,000 patients since inception. Patients that are unable to leave their home rely on over 100 doctors in the Medvisit network for the treatment of acute and episodic illness and injury. The combination of pharmacy and doctor home visits through the Mednow platform has created synergies that greatly benefit patients. By offering a comprehensive review of their medications and treatment plan prior to in-home medication visits, Mednow and Medvisit are able to provide the highest level of care at the forefront of chronic disease management. Through the Medvisit patient network, Mednow is well positioned to offer a full platform of services to a large subset of patients that can benefit greatly from a full suite of digital healthcare and delivery services. Mednow is focused on improving delivery of pharmacy services in Canada through digitization to provide better patient access to pharmacists, doctors and other healthcare professionals. Mednow offers instant access to pharmacists in the Mednow app (Apple | Android | web browser) or on the phone (1-855-MEDNOW-1) and offers fast, free delivery of prescription medication to patients across Canada.
Reported Earnings • Dec 01Full year 2022 earnings released: CA$1.37 loss per share (vs CA$0.49 loss in FY 2021)Full year 2022 results: CA$1.37 loss per share (further deteriorated from CA$0.49 loss in FY 2021). Revenue: CA$16.6m (up CA$16.2m from FY 2021). Net loss: CA$29.6m (loss widened 230% from FY 2021).
공시 • Jun 16+ 1 more updateMednow Inc. Announces CEO ChangesMednow Inc. announced that Ali Reyhany, the company’s current director, President and Chairman of the board, has been selected to replace Karim Nassar, as Chief Executive Officer effective June 15. As the company’s founder and architect of its culture, the Company’s board of directors believes Mr. Reyhany is singularly qualified to serve as Chief Executive Officer.
Reported Earnings • Jun 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: CA$6.14m (up CA$6.01m from 3Q 2021). Net loss: CA$5.66m (loss widened 159% from 3Q 2021).
공시 • Apr 27Mednow Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year Ending April 30, 2022Mednow Inc. provided earnings guidance for the third quarter of fiscal year ending April 30, 2022. For the quarter, Company expects revenue of $5 million to $5.5 million.
공시 • Apr 16Mednow Inc., Annual General Meeting, Jun 07, 2022Mednow Inc., Annual General Meeting, Jun 07, 2022. Location: 10th Floor, 595 Howe Street, BC V6C Vancouver Canada
공시 • Apr 03Mednow Inc. (TSXV:MNOW) completed the acquisition of Mednow East Inc. from Amir Ali Reyhany-Bozorg, Felipe Campusano and Karim Nassar and others.Mednow Inc. (TSXV:MNOW) entered into a share purchase agreement to acquire Mednow East Inc. for CAD 1.4 million from Amir Ali Reyhany-Bozorg, Felipe Campusano and Karim Nassar and others on March 4, 2022. Mednow Inc. shall acquire all of the issued and outstanding shares of Mednow East, in consideration for an aggregate cash payment of approximately CAD 65,578 and the Company’s agreement to convert approximately CAD 1,374,422 owed by Mednow East to the Mednow Inc. into a non-interest bearing on-demand convertible promissory note and the Note can be satisfied by the payment of cash or the issuance of 2,095 Class A Special Shares of Mednow East at a deemed price of $655.78 per share. Upon closing of the Share Purchase Agreement, Mednow East’s revenue and expenses will be consolidated with those of Mednow and the Pharmacy Agreement between the two parties will be terminated. The debt of approximately CAD 1,374,422 extended to Mednow East by the Company was used to fund Mednow East’s working capital and provide support for its operations. The Transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval. Mednow Inc. (TSXV:MNOW) completed the acquisition of Mednow East Inc. from Amir Ali Reyhany-Bozorg, Felipe Campusano and Karim Nassar and others on April 1, 2022.
공시 • Feb 25Mednow Inc. Provides Earnings Guidance for the Years of 2022 and 2023Mednow Inc. provided earnings guidance for the years of 2022 and 2023. For the calendar year 2022, revenue is forecasted to range between CAD 42.5 million to CAD 47.5 million. Revenue for 2023 is forecasted to range between CAD 105 million to CAD 110 million.
공시 • Feb 24Mednow Inc. (TSXV:MNOW) completed the acquisition of Liver Care Canada Inc.Mednow Inc. (TSXV:MNOW) entered into an agreement to acquire Liver Care Canada Inc. for CAD 0.07 million on December 20, 2021. In a related transaction, Mednow entered into an agreement to acquire London Pharmacare. Under the agreement, Mednow will acquire Liver Care for an initial cash payment of CAD 0.07 million and two subsequent earnout payments in the amount of 0.1x of the revenue generated by Liver Care in each of its 2022 and 2023 financial years. The Transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval. Mednow Inc. (TSXV:MNOW) completed the acquisition of Liver Care Canada Inc. on February 23, 2022.
공시 • Dec 23Mednow Inc. (TSXV:MNOW) entered into a share purchase agreement to acquire London Pharmacare Inc. from Felipe Campusano and others for CAD 0.59 million.Mednow Inc. (TSXV:MNOW) entered into a share purchase agreement to acquire London Pharmacare Inc. from Felipe Campusano and others for CAD 0.59 million on December 20, 2021. The consideration includes an initial cash payment of CAD 0.59 million and two subsequent earn-out payments in the amount of 0.1x of the revenue generated by London Pharmacare in each of its 2022 and 2023 financial years. In a related transaction, Mednow entered into an agreement to acquire Liver Care Canada Inc. for CAD 0.07 million. In the last fiscal year, London Pharmacare and Liver Care Canada generated approximately an aggregate of CAD 21.3 million in revenue and CAD 2.1 million in gross profits from selling prescription medications and diagnostic services to its patients. The transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval.
공시 • Dec 22Mednow Inc. (TSXV:MNOW) entered into an agreement to acquire Liver Care Canada Inc. for CAD 0.07 million.Mednow Inc. (TSXV:MNOW) entered into an agreement to acquire Liver Care Canada Inc. for CAD 0.07 million on December 20, 2021. In a related transaction, Mednow entered into an agreement to acquire London Pharmacare. Under the agreement, Mednow will acquire Liver Care for an initial cash payment of CAD 0.07 million and two subsequent earnout payments in the amount of 0.1x of the revenue generated by Liver Care in each of its 2022 and 2023 financial years. The Transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval.
공시 • Dec 14Mednow Inc. (TSXV:MNOW) completed the acquisition of Infusicare Canada Inc. from Amir Ali Reyany-Bozorg, Felipe Campusano and others for CAD 1.9 million.Mednow Inc. (TSXV:MNOW) entered into an agreement to acquire Infusicare Canada Inc. from Amir Ali Reyany-Bozorg, Felipe Campusano and others for CAD 1.9 million on November 18, 2021. The consideration will be paid in cash. Infusicare Canada generated revenues of CAD 9.3 million in fiscal year 2020. The transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval. Mednow Inc. (TSXV:MNOW) completed the acquisition of Infusicare Canada Inc. from Amir Ali Reyany-Bozorg, Felipe Campusano and others on December 13, 2021.
공시 • Sep 24Mednow Inc. (TSXV:MNOW) entered into a share purchase agreement to acquire Mednow Pharmacy Inc. from Amir Ali Reyhany-Bozorg, Karim Nassar and Felipe Campusano for CAD 0.074 million.Mednow Inc. (TSXV:MNOW) entered into a share purchase agreement to acquire Mednow Pharmacy Inc. from Amir Ali Reyhany-Bozorg, Karim Nassar and Felipe Campusano for CAD 0.074 million on September 22, 2021. As part of consideration, Mednow Inc. will pay CAD 0.074 million in cash. Post-acquisition, Mednow will own 100% of Mednow Pharmacy Inc. The transaction is subject to corporate and regulatory approvals, including TSX Venture Exchange approval.
공시 • Aug 08Mednow Inc. (TSXV:MNOW) acquired 2716725 Ontario Inc. for CAD 2 million.Mednow Inc. (TSXV:MNOW) acquired 2716725 Ontario Inc. for CAD 2 million on August 6, 2021. Under the terms of transaction, Mednow will pay CAD 1.32 million in cash upon closing and a conditional earn-out of up to CAD 0.68 million subject to profitability milestones. In latest fiscal year, Medvisit earned revenue of approximately CAD 3 million and a gross profit of approximately CAD 0.79 million. Mednow Inc. (TSXV:MNOW) completed the acquisition of 2716725 Ontario Inc. on August 6, 2021.
분석 기사 • Jun 24Is Mednow (CVE:MNOW) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Executive Departure • Jun 10Chief Financial Officer Joshua Lebovic has left the companyDuring their tenure, earnings grew by 609% annually compared to the industry average of 117%. We don't have any record of a personal shareholding under Joshua's name. Joshua is the only executive to leave the company over the last 12 months.
공시 • Mar 21Mednow Inc. Appoints Carey Lai as Director of Pharmacy OperationsMednow Inc. announced a significant operational milestone in advancing its national expansion strategy. Mednow has filed an application for a pharmacy license with the Manitoba College of Pharmacists through a wholly-owned subsidiary, Mednow Pharmacy MB Ltd. Upon successful application, this wholly-owned entity will be a licensed pharmacy that will be regulated by Manitoba College of Pharmacists as well as provincial and federal regulatory bodies with oversight of pharmacy practices. In conjunction with this application, the Company has appointed Carey Lai as Director of Pharmacy Operations for Manitoba and Saskatchewan. Mr. Lai has over 15 years’ experience in pharmacy operations.
분석 기사 • Mar 11We're Hopeful That Mednow (CVE:MNOW) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...